ILiAD Biotechnologies key facts
- Developer of a medical vaccine designed to prevent and offer treatment for human disease caused by Bordetella pertussis.
- It has raised $214.6M across 7 recorded rounds; the latest was Later Stage VC (Series B) ($115.0M) in Feb 2026.
- Notable investors include RA Capital Management, National Institutes of Health, European Union, BNP Paribas Asset Management, Knott Partners Management — 11 tracked in total.
- ILiAD Biotechnologies has filed 11 Form Ds with the SEC since 2017, most recently Feb 2026 ($115.5M sold to 36 investors).
- Status: Privately Held (backing).
Who backs ILiAD Biotechnologies
11+- ·The complete investor list: 11 names
- ·Watch ILiAD Biotechnologies: the Monday email on marks, rounds and moves
ILiAD Biotechnologies funding rounds
7 roundsHow much has ILiAD Biotechnologies raised?
ILiAD Biotechnologies has raised $215 million across 7 recorded rounds since 2017. The largest was a $675,220 seed round in Jan 2018; the most recent was an $115 million Series B in Feb 2026.
ILiAD Biotechnologies has filed 11 Form Ds with the SEC since 2017, most recently in Feb 2026 ($116 million sold to 36 investors).
ILiAD Biotechnologies investors
11 investors are on record for ILiAD Biotechnologies, including RA Capital Management, National Institutes of Health, European Union and BNP Paribas Asset Management. The Series B in Feb 2026 drew 2 investors.
About ILiAD Biotechnologies
Developer of a medical vaccine designed to prevent and offer treatment for human disease caused by Bordetella pertussis. The company's vaccine specializes in attenuated pertussis, inducing the immune system to produce protective antibodies to eradicate the infection, enabling patients to recover from whooping cough and other serious diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Weston, FL, United States
- Founded
- 2012
- Employees
- 25
- Website
- iliadbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ILiAD Biotechnologies doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.